Home > Neurology > MS Virtual 2020 > Novel Treatment Directions > Functional potential of gut microbiome in paediatric MS

Functional potential of gut microbiome in paediatric MS

MS Virtual 2020
A study using metagenomic sequencing found differences in the functional potential of the gut microbiome of patients with paediatric-onset MS compared with controls at various metabolic pathways [1]. Exposure to disease-modifying therapy (DMT) was associated with enrichment of pathways involved in promoting central nervous system remyelination. A Canadian group examined the gut microbiome functional diversity and potential by metagenomic analysis of stool samples from 20 patients ≤21 years old (mean age 16.1 years) with paediatric-onset MS and from 20 matched controls. Exposure to antibiotics or corticosteroids 30 days prior to sampling was not allowed. MS patients were either DMT-naïve (n=8) or used interferon-beta or glatiramer acetate (n=12). There were no significant differences in functional alpha-diversity by disease or DMT status. However, differential analysis of metabolic pathways revealed that MS patients exhibited higher Archaea-...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on